Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.

Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.

Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated...

Full description

Bibliographic Details
Main Authors:	Marion Adelfinger, Ivaylo Gentschev, Julio Grimm de Guibert, Stephanie Weibel, Johanna Langbein-Laugwitz, Barbara Härtl, Hugo Murua Escobar, Ingo Nolte, Nanhai G Chen, Richard J Aguilar, Yong A Yu, Qian Zhang, Alexa Frentzen, Aladar A Szalay
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4122492?pdf=render

Similar Items

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
by: Marion Adelfinger, et al.
Published: (2015-07-01)

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
by: Sandeep S Patil, et al.
Published: (2012-01-01)

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
by: Ivaylo Gentschev, et al.
Published: (2010-01-01)

Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.
by: Ulrike Donat, et al.
Published: (2012-01-01)

Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.
by: Ivaylo Gentschev, et al.
Published: (2011-01-01)

Oncolytic Virotherapy of Canine and Feline Cancer
by: Ivaylo Gentschev, et al.
Published: (2014-05-01)

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68
by: Ivaylo Gentschev, et al.
Published: (2010-01-01)

Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models
by: Alexander Cecil, et al.
Published: (2019-01-01)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
by: Wang Huiqiang, et al.
Published: (2012-08-01)

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
by: Liu Hui, et al.
Published: (2009-07-01)

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
by: Bedognetti Davide, et al.
Published: (2011-10-01)

Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.
by: Ivaylo Gentschev, et al.
Published: (2012-01-01)

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice
by: Yu Yong A, et al.
Published: (2011-09-01)

Oncolytic vaccinia therapy of squamous cell carcinoma
by: Yu Yong A, et al.
Published: (2009-07-01)

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients
by: Patil Sandeep S, et al.
Published: (2012-01-01)

Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies
by: Sturm Julia B, et al.
Published: (2011-10-01)

Efficient Selection of Recombinant Fluorescent Vaccinia Virus Strains and Rapid Virus Titer Determination by Using a Multi-Well Plate Imaging System
by: Mingyu Ye, et al.
Published: (2021-08-01)

Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine
by: Eike Binz, et al.
Published: (2017-09-01)

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas
by: Ivan Petrov, et al.
Published: (2020-07-01)

Intratumoral INF-Î³ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
by: Christina Kober, et al.
Published: (2015-01-01)

Design of oncolytic viruses for the imaging and treatment of cancer: The vaccinia construct GLV-1h153 carrying the human sodium iodide symporter
by: Haddad, Dana
Published: (2011)

Oncolytic Therapy with Vaccinia Virus GLV-1h68 - Comparative Microarray Analysis of Infected Xenografts and Human Tumor Cell Lines -
by: Worschech, Andrea
Published: (2010)

Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms
by: Linus D. Kloker, et al.
Published: (2020-07-01)

Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI).
by: Stephanie Weibel, et al.
Published: (2013-01-01)

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
by: Ting Huang, et al.
Published: (2015-01-01)

Oncolytic Viruses
by: Nanhai G. Chen, et al.
Published: (2012-01-01)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
by: Dana Haddad, et al.
Published: (2016-01-01)

Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
by: Schäfer Simon, et al.
Published: (2012-08-01)

A Modified Limiting Dilution Method for Monoclonal Stable Cell Line Selection Using a Real-Time Fluorescence Imaging System: A Practical Workflow and Advanced Applications
by: Mingyu Ye, et al.
Published: (2021-02-01)

Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter.
by: Dana Haddad, et al.
Published: (2012-01-01)

Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
by: Desislava Tsoneva, et al.
Published: (2017-06-01)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
by: Stephen eThorne
Published: (2014-06-01)

Theranostic Potential of Oncolytic Vaccinia Virus
by: Juan J Rojas, Steve H Thorne
Published: (2012-01-01)

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
by: Dobrin D. Draganov, et al.
Published: (2019-03-01)

Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
by: Mittra Arjun, et al.
Published: (2011-03-01)

Characterization of the Role of Necroptosis for Oncolytic Vaccinia Efficacy
Published: (2020)

Oncolytic vaccinia virus for the treatment of liver cancer
by: Dave, Rajiv Vipool
Published: (2014)

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
by: Dobrin D. Draganov, et al.
Published: (2021-10-01)

Bio-Engineering Vaccinia Viruses for Increased Oncolytic Potential
by: Pelin, Adrian
Published: (2019)

The Combination of Carboxylesterase-Expressing Oncolytic Vaccinia Virus and Irinotecan
by: Becker, Michelle Caitlin
Published: (2013)